SCHEMBL6506355

SCHEMBL6506355

O=C(O)c1ccccc1Sc1nc(-c2ccccc2)cc2nccn12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.43
MAP4K2 Q12851 5/20 0.40
SYK P43405 4/20 0.40
MAP4K4 O95819 2/20 0.40
PKN2 Q16513 2/20 0.40
AURKB Q96GD4 2/20 0.40
SLK Q9H2G2 2/20 0.40
AURKA O14965 1/20 0.40
JAK2 O60674 1/20 0.40
INSR P06213 1/20 0.40
LCK P06239 1/20 0.40
LYN P07948 1/20 0.40
RET P07949 1/20 0.40
ROS1 P08922 1/20 0.40
SRC P12931 1/20 0.40
FER P16591 1/20 0.40
KDR P35968 1/20 0.40
BLK P51451 1/20 0.40
RPS6KA3 P51812 1/20 0.40
PRKCD Q05655 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2513786 0.68 DYRK1A (0.44) MAP4K4AURKAJAK2RETKDR
SCHEMBL126695 0.67 POLB (0.59) KDM4ELMNASMN1; SMN2DHODHALDH1A1
SCHEMBL1482567 0.66 POLB (0.74) KDM4ESMN1; SMN2ALDH1A1RAB9APOLB
SCHEMBL29888792 0.66 POLB (0.74) KDM4ESMN1; SMN2ALDH1A1RAB9APOLB
SCHEMBL6420521 0.65 TDP1 (0.47) MAP4K2SYKMAP4K4PKN2AURKB
SCHEMBL9460748 0.64 POLB (0.71) KDM4ESMN1; SMN2ALDH1A1RAB9APOLB
SCHEMBL4628032 0.63 POLB (0.53) KDM4ELMNASMN1; SMN2ALDH1A1POLB
SCHEMBL5315910 0.63 MAP4K2 (0.42) MAP4K2SYKMAP4K4PKN2AURKB
SCHEMBL8639079 0.62 POLB (0.57) PTPN5KDM4ELMNASMN1; SMN2ALDH1A1
SCHEMBL231042 0.61 SIRT1 (0.71) KDM4ELMNASMN1; SMN2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911443-B2 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-06-28 US disclosed
EP-1278750-B1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-08-04 EP disclosed
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-03-18 US disclosed
EP-1278750-A1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES Bayer Aktiengesellschaft (DE) 2003-01-29 EP disclosed
WO-2001083485-A1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives XRCC6, XRN2, HRH2 PTPN5 1137/4885MAP4K2 2126/4885SYK 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.